How This Evidence Evolved
Adrenal Incidentaloma Imaging
From surgical exploration to imaging-based risk stratification and reducing unnecessary follow-up
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
Follow-up studies, subgroup analyses, and real-world validation
Integration into clinical practice guidelines and recommendations
ESE/ENSAT 2023: homogeneous ≤10 HU: no further imaging, regardless of size. Endocrine workup includes 1-mg DST. Surgery usually for >4 cm with inhomogeneity or HU >20. Discuss other lesions in a multidisciplinary expert meeting.
Current standard of care and ongoing research directions
Landmark Trials in This Story
Non-small cell lung carcinoma: usefulness of unenhanced helical CT of the adrenal glands in an unmonitored environment.
Adrenal mass characterization with unenhanced CT.
Adrenal masses: characterization with combined unenhanced and delayed enhanced CT.
Combined CT: sensitivity 98%, specificity 92% (166 masses).
Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role?
MRI at 20% SI decrease: sensitivity 67%, specificity 100% (>10 HU).
Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee.
Imaging-based management algorithm for adrenal incidentalomas
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors
Evidence-based management recommendations
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.